Skip to main content
      RT @doctorRBC: Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab
      ⭐️mean change and res

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
      RT @doctorRBC: Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise
      ⭐️significan

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl
      RT @Janetbirdope: #Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting

      Janet Pope Janetbirdope

      4 years 5 months ago
      #Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting for comorbidities- so many diagnoses with RA ⬇️outcomes only defined as >1 drug #EULAR2021 @RheumNow OP0098 https://t.co/lMazBDTPw1
      RT @Stiddyo: #OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures

      Paul Studenic Stiddyo

      4 years 5 months ago
      #OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE
      RT @Stiddyo: #OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 resu

      Paul Studenic Stiddyo

      4 years 5 months ago
      #OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
      RT @ejdein1: #Eular2021 OP0289:
      ⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS
      ⭐️Remission on-Rx: SLEDAI 0, P

      Eric Dein ejdein1

      4 years 5 months ago
      #Eular2021 OP0289: ⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS ⭐️Remission on-Rx: SLEDAI 0, Pred<5mg, maintenance IS ⭐️LDAS: SLEDAI<=2 wo pred or IS ⭐️LLDAS: SLEDAI <=4, no maj organ, no new features, pred <=7.5+main These states have ⬇️ damage accrual, rec'd T2T @Rhuemnow
      RT @Janetbirdope: My toe hurts &amp; it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbid

      Janet Pope Janetbirdope

      4 years 5 months ago
      My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbidities to worse outcomes if CRF in gout. HTN⬆️ Gout has SNIPs assoc w HTN & May be the cause. Incident Gout assoc with Acute coronary syndrome OP0193 OP0192 #EULAR2021 @RheumNow @eular_org https://t.co/CS6o0T1FL2
      RT @ejdein1: #EULAR2021 OP0290: Cluster analysis of APLS
      4 Clusters:
      ⭐️ 2ndary APS, non-criteria
      ⭐️ ♂️ with

      Eric Dein ejdein1

      4 years 5 months ago
      #EULAR2021 OP0290: Cluster analysis of APLS 4 Clusters: ⭐️ 2ndary APS, non-criteria ⭐️ ♂️ with CV risks ⭐️OB morbidity ⭐️Isolated LA + @RheumNow
      A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay #EULAR2021

      Dr. Jonathan Kay reviews three RA abstracts from t

      Dr. John Cush RheumNow

      4 years 5 months ago
      A Triple Header of RA Plenary Abstracts: Dr. Jonathan Kay #EULAR2021 Dr. Jonathan Kay reviews three RA abstracts from the opening plenary session at the EULAR 2021 virtual meeting: abstract OP0012; abstract OP0007; and abstract OP0006. https://t.co/6GhSLXqysd https://t.co/h2k00GzHE5
      RT @Janetbirdope: Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% wi

      Janet Pope Janetbirdope

      4 years 5 months ago
      Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% with advanced Rx were difficult to treat vs 39% if > 1 ts\bDMARDs. Worse pts had ⬆️disease duration. Drug resistance over time? POS0405 @RheumNow #EULAR2021 @eular_org
      RT @LRPow79: Imagine being top expert for 37 years. World RENOWNED, won 🏅’s. Then there’s a crisis, IN YOUR FIELD

      🇵🇱Reality Dose🇺🇸 LRPow79

      4 years 5 months ago
      Imagine being top expert for 37 years. World RENOWNED, won 🏅’s. Then there’s a crisis, IN YOUR FIELD, & as you step up, you’re degraded at every turn by a con man. Yet you carry on your duty cuz 🇺🇸 depends on it. THAT’S professionalism. THAT’S Dr Fauci https://t.co/DkVyfAQHsp
      RT @DrAiLynTan: Stop #smoking!
      Smoking is not good for you &amp; others!

      👉🏽Passive smoking exposures during child

      Dr Ai Lyn Tan DrAiLynTan

      4 years 5 months ago
      Stop #smoking! Smoking is not good for you & others! 👉🏽Passive smoking exposures during childhood & adulthood associated with increased risk of #RheumatoidArthritis Could favour citrullination in genetically proned people By @YannNgyn OP0012 #EULAR2021 #rheumatoid https://t.co/ImDR0aLAXd
      ×